Kinagen’sRAF Blockade drug candidate is differentiated as a potent, selective inhibitor of key signals driving over one third of human cancers including breast, lung, pancreatic and colorectal cancers as well as melanoma. Via its unique mechanism of action, RAF Blockade addresses the limitations of other approaches.

RAF Blockade has demonstrated single agent antitumor, antiangiogenic and anti-lymphangiogenic effects in multiple animal models of solid tumor cancers. This multi-pronged anticancer activity targets the tumor directly as well as non-cancerous, tumor-associated stroma cells to cut off tumors' blood supply and stem the deadly spread of disease, providing more durable benefit to patients.

RAF Blockade is unique in its ability to block B/C-RAF heterodimer formation and phosphorylaton of C-RAF at S338 via a non-ATP competitive mechanism of action. This mechanism addresses limitations of other RAF-targeted drugs. Further, RAF Blockade's antiangiogenic activity is exerted by a unique mechanism that addresses the limitations of existing antiangiogenic drugs, including VEGF-targeted therapies.

Unprecedented selectivity, oral bioavailability, pharmacokinetic, metabolic and outstanding safety properties have been characterized, and RAF Blockade is poised to move into IND-enabling studies. Clinical development plans are in place to rapidly establish clinical proof of concept in a molecularly defined, high-need patient population.